1. Tsokos GC, ed. Systemic lupus erythematosus: basic, applied and clinical aspects. San Diego (CA): Academic Press; 2017.

2. Rubin RL. Chapter 56 - drug-induced lupus. In: Tsokos GC, ed. Systemic lupus erythematosus. 2nd ed. London: Academic Press; 2020. p.535-47. [DOI:10.1016/B978-0-12-814551-7.00056-8]

3. Borchers AT, Keen CL, Gershwin ME. Drug-induced lupus: an update. Ann N Y Acad Sci 2007;1108:196-207. [DOI:10.1196/annals.1422.019]

4. Yung RL, Richardson BC. Chapter 22 - Drug-induced lupus mechanisms. In: Lahita RG, ed. Systemic lupus erythematosus. 5th ed. San Diego (CA): Academic Press; 2011. p.385-403. [DOI:10.1016/B978-0-12-374994-9.10022-1]

5. Williams EL, Gadola S, Edwards CJ. Anti-TNF-induced lupus. Rheumatology (Oxford) 2009;48:716-20. [DOI:10.1093/rheumatology/kep080]

6. De Bandt M, Sibilia J, Le Loët X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 2005;7:R545-51. [DOI:10.1186/ar1715]

7. Costa MF, Said NR, Zimmermann B. Drug-induced lupus due to anti-tumor necrosis factor α agents. Semin Arthritis Rheum 2008;37:381-7. [DOI:10.1016/j.semarthrit.2007.08.003]

8. de Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, de Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum 2005;52:2192-201. [DOI:10.1002/art.21190]

9. Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008;22:847-61. [DOI:10.1016/j.berh.2008.09.008]

10. Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFalpha. Ann Rheum Dis 2005;64:403-7. [DOI:10.1136/ard.2004.024182]

11. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81. [DOI:10.1002/art.27584]

12. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73. [DOI:10.1002/art.21972]

13. Solomon DH, Kavanaugh AJ, Schur PH; American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing. Arthritis Rheum 2002;47:434-44. [DOI:10.1002/art.10561]

14. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:1810-52. [DOI:10.1161/CIR.0b013e31829e8807]

15. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol 2000;53:424-32. [DOI:10.1136/jcp.53.6.424]

16. Rubin RL. Chapter 56 - drug-induced lupus. In: Tsokos GC, ed. Systemic lupus erythematosus. 2nd ed. London: Academic Press; 2020. p.535-47. [DOI:10.1016/B978-0-12-814551-7.00056-8]

17. Shmerling RH, Delbanco TL. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991;91:528-34. [DOI:10.1016/0002-9343(91)90190-9]

18. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 20075;146:797-808. [DOI:10.7326/0003-4819-146-11-200706050-00008]

19. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.

20. Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. J Psoriasis Psoriatic Arthritis 2019;4:31-58. [DOI:10.1177/2475530318812244]

21. Eriksson C, Engstrand S, Sundqvist KG, Rantapää-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann Rheum Dis 2005;64:403-7. [DOI:10.1136/ard.2004.024182]

22. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-1. [DOI:10.1038/37022]

23. Charles PJ, Smeenk RJT, De Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:2383-90. https://doi.org/10.1002/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D [DOI:10.1002/1529-0131(200011)43:113.0.CO;2-D]

24. Ramos-Casals M, Perez-Alvarez R, Diaz-Lagares C, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9:188-93. [DOI:10.1016/j.autrev.2009.10.003]

25. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90. [DOI:10.1016/S0140-6736(00)02530-7]

26. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. [DOI:10.1002/art.20217]

27. Lachmann PJ. Chapter 4 - The amplification loop of the complement pathways. In: Alt FW, ed. Advances in immunology. Vol. 104. Amsterdam: Academic Press; 2009. p.115-49. [DOI:10.1016/S0065-2776(08)04004-2]

28. Feldmann M, Maini RN. Anti-TNFalpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163-96. [DOI:10.1146/annurev.immunol.19.1.163]